PMID- 25074640
OWN - NLM
STAT- MEDLINE
DCOM- 20151218
LR  - 20221207
IS  - 1740-634X (Electronic)
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 40
IP  - 2
DP  - 2015 Jan
TI  - Effects of social interaction and warm ambient temperature on brain hyperthermia 
      induced by the designer drugs methylone and MDPV.
PG  - 436-45
LID - 10.1038/npp.2014.191 [doi]
AB  - 3,4-Methylenedioxymethcathinone (methylone) and 3,4-methylenedioxypyrovalerone 
      (MDPV) are new drugs of abuse that have gained worldwide popularity. These drugs 
      are structurally similar to 3,4-methylenedioxymethamphetamine (MDMA) and share 
      many of its physiological and behavioral effects in humans, including the 
      development of hyperthermia during acute intoxication. Here, we examined the 
      effects of methylone (1-9 mg/kg, s.c.) or MDPV (0.1-1.0 mg/kg, s.c.) on brain 
      temperature homeostasis in rats maintained in a standard laboratory environment 
      (single-housed in a quiet rest at 22  degrees C) and under conditions that model human 
      drug use (social interaction and 29  degrees C ambient temperature). By simultaneously 
      monitoring temperatures in the nucleus accumbens, temporal muscle, and facial 
      skin, we assessed the effects of methylone and MDPV on intra-brain heat 
      production and cutaneous vascular tone, two critical factors that control brain 
      temperature responses. Both methylone and MDPV dose-dependently increased brain 
      temperature, but even at high doses that induced robust locomotor activation, 
      hyperthermia was modest in magnitude (up to  approximately 2  degrees C). Both drugs also induced 
      dose-dependent peripheral vasoconstriction, which appears to be a primary 
      mechanism determining the brain hyperthermic responses. In contrast to the 
      powerful potentiation of MDMA-induced hyperthermia by social interaction and warm 
      ambient temperature, such potentiation was absent for methylone and minimal for 
      MDPV. Taken together, despite structural similarities to MDMA, exposure to 
      methylone or MDPV under conditions commonly associated with human drug use does 
      not lead to profound elevations in brain temperature and sustained 
      vasoconstriction, two critical factors associated with MDMA toxicity.
FAU - Kiyatkin, Eugene A
AU  - Kiyatkin EA
AD  - Intramural Research Program, NIDA-NIH, Baltimore, MD, USA.
FAU - Kim, Albert H
AU  - Kim AH
AD  - Intramural Research Program, NIDA-NIH, Baltimore, MD, USA.
FAU - Wakabayashi, Ken T
AU  - Wakabayashi KT
AD  - Intramural Research Program, NIDA-NIH, Baltimore, MD, USA.
FAU - Baumann, Michael H
AU  - Baumann MH
AD  - Intramural Research Program, NIDA-NIH, Baltimore, MD, USA.
FAU - Shaham, Yavin
AU  - Shaham Y
AD  - Intramural Research Program, NIDA-NIH, Baltimore, MD, USA.
LA  - eng
GR  - UL1 TR000448/TR/NCATS NIH HHS/United States
GR  - ImNIH/Intramural NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20140730
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Benzodioxoles)
RN  - 0 (Designer Drugs)
RN  - 0 (Psychotropic Drugs)
RN  - 0 (Pyrrolidines)
RN  - 44RAL3456C (Methamphetamine)
RN  - L4I4B1R01F (methylone)
RN  - 0 (Synthetic Cathinone)
SB  - IM
MH  - Animals
MH  - Benzodioxoles/*pharmacology
MH  - Body Temperature/drug effects/physiology
MH  - Brain/*drug effects/physiopathology
MH  - Designer Drugs/*pharmacology
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Fever/chemically induced/physiopathology
MH  - Homeostasis/drug effects/physiology
MH  - *Interpersonal Relations
MH  - Locomotion/drug effects/physiology
MH  - Methamphetamine/*analogs & derivatives/pharmacology
MH  - Psychotropic Drugs/pharmacology
MH  - Pyrrolidines/*pharmacology
MH  - Rats, Long-Evans
MH  - *Temperature
MH  - Vasoconstriction/drug effects/physiology
MH  - Synthetic Cathinone
PMC - PMC4443958
EDAT- 2014/07/31 06:00
MHDA- 2015/12/19 06:00
PMCR- 2016/01/01
CRDT- 2014/07/31 06:00
PHST- 2014/06/04 00:00 [received]
PHST- 2014/07/24 00:00 [revised]
PHST- 2014/07/25 00:00 [accepted]
PHST- 2014/07/31 06:00 [entrez]
PHST- 2014/07/31 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
PHST- 2016/01/01 00:00 [pmc-release]
AID - npp2014191 [pii]
AID - 10.1038/npp.2014.191 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2015 Jan;40(2):436-45. doi: 10.1038/npp.2014.191. Epub 
      2014 Jul 30.